A practical approach to the cholesterol guidelines and ASCVD prevention.
Level V
Where this comes from
- Record sourced from PubMed, PMID 32349970.
- Also identified by DOI 10.3949/ccjm.87.s1.02.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Lifestyle factors remain the bedrock of atherosclerotic cardiovascular disease (ASCVD) prevention. Statins remain the first-line therapy for primary and secondary prevention of ASCVD. Physicians are encouraged to discuss the risks and benefits of statins with patients before beginning therapy. Nonstatins and proprotein convertase subtilisin-kexin type 9 inhibitors are recommended for secondary prevention in patients with clinical ASCVD. For patients at intermediate risk of ASCVD, new risk-enhancing factors, including chronic inflammatory conditions and ethnicity, should be considered to better risk stratify these patients.
Medical subject headings
- Atherosclerosis
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Hypercholesterolemia
- Risk Reduction Behavior